| |
| |
|
| Insider
Information: |
Francois Cedric |
| Relationship: |
Chief Executive Office... |
| City: |
Crestwood |
| State: |
KY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
313,662 |
|
|
Indirect Shares
|
1,721,568 |
|
|
| Direct
Value |
$12,311,234 |
|
|
|
Indirect Value
|
$67,571,544 |
|
|
| Total
Shares |
2,035,230 |
|
|
| Total
Value |
$79,882,778 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
5
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -171.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Apellis Pharmaceuticals Inc |
APLS |
Chief Executive Office... |
2024-03-01 |
313,662 |
2024-03-01 |
1,721,568 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
76 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2018-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
384,292 |
714,288 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2020-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
34,375 |
1,066,805 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2021-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
1,222,356 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2022-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
106,244 |
1,340,487 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2022-04-25 |
4 |
AS |
$0.00 |
$0 |
D/D |
(12,500) |
943,440 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
83,447 |
1,048,575 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• – – |
2023-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
13,908 |
1,046,193 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-03 |
4 |
GA |
$0.00 |
$0 |
I/I |
227,221 |
227,221 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
227,221 |
1,044,591 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
380,000 |
664,591 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
380,000 |
607,221 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
26,990 |
637,601 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-05 |
4 |
GA |
$0.00 |
$0 |
I/I |
26,990 |
634,211 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
382,946 |
274,655 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-27 |
4 |
GA |
$0.00 |
$0 |
I/I |
382,946 |
382,946 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-05-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
274,655 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-05-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
20,000 |
654,211 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-09-19 |
4 |
GA |
$0.00 |
$0 |
I/I |
150,000 |
804,211 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-09-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
150,000 |
274,655 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
72,094 |
341,749 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2019-08-15 |
4 |
OE |
$2.14 |
$21,400 |
D/D |
10,000 |
999,288 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2020-08-18 |
4 |
AS |
$30.00 |
$46,290 |
D/D |
(1,543) |
1,096,536 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-19 |
4 |
OE |
$2.67 |
$53,400 |
D/D |
20,000 |
657,601 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-05-17 |
4 |
OE |
$2.67 |
$53,400 |
D/D |
20,000 |
294,655 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2021-07-21 |
4 |
OE |
$4.31 |
$62,107 |
D/D |
14,410 |
1,234,243 |
0 |
- |
|
76 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
